Optimizing Outcomes & Improving Adherence: Use of Long-Acting Injectables in Early Schizophrenia - a podcast by ReachMD

CME credits: 0.50

Valid until: 28-08-2021

Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-improving-adherence-use-long-acting-injectables-early-schizophrenia/11770/

The prevention of a subsequent psychotic episode and resulting hospitalization in people with early phase schizophrenia is a key public health problem with substantial consequences. Previous research has shown that second episodes of psychosis in the same individual respond less well to the same treatment. Therefore, the prevention of psychotic episodes with proper medications and therapies is crucial for their prospects toward longer-term recovery. Unfortunately, adherence to antipsychotic medication is low and long-acting injectable antipsychotic medications are underutilized. New research is emerging that demonstrates how long-acting injectables, which have been traditionally reserved for patients at later periods of their disease, can be utilized for first or early episodes of schizophrenia to achieve optimal outcomes.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD